Showing 361 - 380 results of 1,182 for search '"liver diseases"', query time: 0.08s Refine Results
  1. 361
  2. 362

    A High-Fat, High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice by Kanokwan Jarukamjorn, Nattharat Jearapong, Charinya Pimson, Waranya Chatuphonprasert

    Published 2016-01-01
    “…Excessive fat liver is an important manifestation of nonalcoholic fatty liver disease (NAFLD), associated with obesity, insulin resistance, and oxidative stress. …”
    Get full text
    Article
  3. 363

    Analytical and Clinical Evaluation of a Chemiluminescent Immunoassay to Detect Serum Chitinase-3-like Protein 1 in HBV-Related Liver Diseases by Yanqiang Liao, Se Peng, Lesheng Huang, Zhong Li, Jian Hu, Rui Xu, Wenzhi Tang, Jialing Zhuang

    Published 2024-01-01
    “…Serum chitinase-3-like protein 1 (CHI3L1) is a diagnostic marker for liver diseases, such as hepatocellular carcinoma (HCC). …”
    Get full text
    Article
  4. 364
  5. 365
  6. 366
  7. 367

    Inflammatory Cytokines, Adipocytokines, and Th17/Treg Balance in Patients with Nonalcoholic Fatty Liver Disease following Administration of Dahuang Zhechong Pills by Xiaohua Duan, Jianlin Lv, Hebei Jiang, Kefei Zheng, Yulin Chen

    Published 2022-01-01
    “…The occurrence and development of nonalcoholic fatty liver disease (NAFLD) is related to lipid peroxidation, imbalance of inflammatory response factors, and immune function disorder. …”
    Get full text
    Article
  8. 368
  9. 369

    Model for End-Stage Liver Disease Score Predicts the Mortality of Patients with Coronary Heart Disease Who Underwent Percutaneous Coronary Intervention by You Chen, Min Han, Ying-Ying Zheng, Feng Zhu, Aikebai Aisan, Tunike Maheshati, Yi-Tong Ma, Xiang Xie

    Published 2021-01-01
    “…Evidence shows that liver disease is related to CHD. However, the correlation between the Model for End-Stage Liver Disease (MELD) score and outcomes in patients after percutaneous coronary intervention (PCI) was unclear. …”
    Get full text
    Article
  10. 370
  11. 371

    Effect of Alkaloids from Nelumbinis Plumula against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice by Yong Xie, Yi Zhang, Zebin Guo, Hongliang Zeng, Baodong Zheng

    Published 2016-01-01
    “…This study aimed to investigate the effects of total alkaloids from Nelumbinis Plumula (NPA) on insulin resistance (IR) of high-fat diet- (HFD-) induced nonalcoholic fatty liver disease (NAFLD). Rats were fed with HFD for 8 weeks to induce NAFLD. …”
    Get full text
    Article
  12. 372

    Serum Creatinine in Patients with Advanced Liver Disease Is of Limited Value for Identification of Moderate Renal Dysfunction: Are the Equations for Estimating Renal Function Better? by Jillian MacAulay, Kara Thompson, Bryce A Kiberd, David C Barnes, Kevork M Peltekian

    Published 2006-01-01
    “…However, the best formula to identify patients with advanced liver disease (ALD) and moderate renal dysfunction (GFR 60 mL/min/1.73 m2 or less) is not known. …”
    Get full text
    Article
  13. 373
  14. 374
  15. 375
  16. 376

    Identification of retinol dehydrogenase 10 as a shared biomarker for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus by Fangyu Li, Rui Li, Hongjun Deng

    Published 2025-01-01
    “…BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for type 2 diabetes mellitus (T2DM), and its early identification and intervention offer opportunities for reversing diabetes mellitus.MethodsIn this study, we identified biomarkers for the MASLD dataset (GSE33814, GSE48452) and the T2DM dataset (GSE76895 and GSE89120) by bioinformatics analysis. …”
    Get full text
    Article
  17. 377

    Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease by Sumitro Kosasih, Wong Zhi Qin, Rafiz Abdul Rani, Nazefah Abd Hamid, Ngiu Chai Soon, Shamsul Azhar Shah, Yazmin Yaakob, Raja Affendi Raja Ali

    Published 2018-01-01
    “…The aim of this study was to appraise the relationship between serum fragmented cytokeratin-18(CK-18), controlled attenuation parameter (CAP), and liver steatosis assessed by ultrasound (US) in nonalcoholic fatty liver disease (NAFLD) patients. Methods. Patients who underwent abdominal US were recruited, followed with measurement of CAP using Fibroscan® and serum fragmented CK-18 using enzyme-linked immunosorbent assay. …”
    Get full text
    Article
  18. 378

    A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease by Shaojie Huang, Fei Mu, Fei Li, Wenjun Wang, Haixia Chen, Lu Lei, Yang Ma, Yi Ding, Jingwen Wang

    Published 2020-01-01
    “…Erzhi pill (EZP), a classical traditional Chinese medicine prescription, exerts a potent hepatoprotective effect against metabolic dysfunction-associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”
    Get full text
    Article
  19. 379
  20. 380